Bottom Line: GLP-1 drugs come with body-wide benefits, but physicians are still learning more about the nuances of the medicines, Garg explains
Its approved for people with obesity (a body mass index [BMI] of 30 or more) or overweight (a BMI of 27 or more) with at least 1 weight-related health condition such as high cholesterol, high blood pressure, or type 2 diabetes
In the Falutz 2010 trials, once-daily dosing at 2 mg produced mean IGF-1 increases that normalized toward baseline over the 26-week trial, suggesting some receptor adaptation without complete desensitization
The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure
For now, GLP-1s remain legal in competition
writingoriginal draft preparation: all authors